Spectral Medical Inc. | Income Statement

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
2,672.00
2,964.00
3,089.00
3,545.00
3,806.00
3,840
Cost of Goods Sold (COGS) incl. D&A
4,437.00
4,189.00
4,222.00
4,332.00
4,010.00
3,568
Gross Income
1,765.00
1,225.00
1,133.00
787.00
204.00
272
SG&A Expense
9,115.00
8,376.00
7,946.00
8,669.00
3,049.00
2,023
EBIT
11,376.00
10,107.00
9,612.00
9,591.00
3,278.00
1,980
Non Operating Income/Expense
10.00
54.00
5.00
626.00
661.00
509
Pretax Income
11,307.00
10,101.00
9,524.00
10,149.00
3,939.00
2,489
Income Tax
-
609.00
-
-
-
-
Consolidated Net Income
11,307.00
9,492.00
9,524.00
10,149.00
3,939.00
2,489
Net Income
11,307.00
9,492.00
9,524.00
10,149.00
3,939.00
2,489
Net Income After Extraordinaries
11,307.00
9,492.00
9,524.00
10,149.00
3,939.00
2,489
Net Income Available to Common
11,307.00
9,492.00
9,524.00
10,149.00
3,939.00
2,489
EPS (Basic)
0.09
0.06
0.05
0.05
0.02
0.01
Basic Shares Outstanding
128,265.10
154,541.00
188,064.60
204,679.30
207,329.20
220,172.70
EPS (Diluted)
0.09
0.06
0.05
0.05
0.02
0.01
Diluted Shares Outstanding
128,265.10
154,541.00
188,064.60
204,679.30
207,329.20
220,172.70
EBITDA
11,138.00
9,902.00
9,440.00
9,367.00
3,056.00
1,750
Other Operating Expense
496.00
506.00
533.00
135.00
25.00
229
Non-Operating Interest Income
59.00
60.00
83.00
68.00
-
-

About Spectral Medical

View Profile
Address
135 The West Mall
Toronto Ontario M9C 1C2
Canada
Employees -
Website http://www.spectraldx.com
Updated 07/08/2019
Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. Its products include Endotoxin Activity Assay (EAA), Toraymyxin, and proprietary reagents. The EAA is use for the diagnostic of endotoxin activity in human whole blood.